Effects of the Laotian generic version of Capisete Tablets/Caposetinib

Capivasertib Tablets/Capivasertib (Capivasertib) is an oral AKT inhibitor that mainly blocks the growth and survival mechanism of cancer cells by targeting the PI3K/AKT signaling pathway. It has shown efficacy in a variety of solid tumors, especially in the treatment of HR+/HER2-type advanced breast cancer. In recent years, since the drug has not yet been fully launched in China or entered into medical insurance, some patients have turned their attention to the overseas generic drug market, especially the Laos version of Lucius Pharmaceuticals.

The Laos Lucius version of Carpisete Tablets generic drug has attracted attention due to its high cost performance. From the composition point of view, these generic drugs are basically consistent with the original drugs in terms of raw material ingredients, drug concentration, preparation specifications (such as200mg). According to third-party drug testing data, the Lucius generic drug is also quite comparable in terms of drug dissolution and bioavailability, indicating that its mechanism of action and pharmacokinetic characteristics in the body are basically consistent with the original drug. In actual use, some patients reported that its effect on relieving tumor progression and its ability to control the disease were satisfactory.

It is worth noting that although Lao generic drugs have made significant progress in quality control, because they are non-original products, their drug approval process and production quality supervision level still lag behind those of European and American original pharmaceutical companies. Therefore, when choosing to use generic drugs, it is recommended that patients make a reasonable evaluation under the guidance of a professional doctor and ensure that the source of the drug is regular. At the same time, the price advantage of the Lao version of generic drugs is obvious. Taking the specification of 200mg × 64 tablets as an example, the market price is about more than 3,000 yuan, which is several times cheaper than the original drug. It has a smaller financial burden on patients who take it for a long time, and is especially suitable for patients who pay for themselves.

Reference materials:https://www.drugs.com/mtm/capivasertib.html